AssetMark’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
Other funds holding KNSA
AssetMark's KNSA Position: Q3 2026 in Review
AssetMark increased its Kiniksa Pharmaceuticals (KNSA) stake by 760% in Q3 2026, buying an estimated $2.8K and bringing the position to 43 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.
AssetMark first reported a position in KNSA in Q3 2025 and has held it in 5 quarters since. 226 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.
- AssetMark held 43 shares of Kiniksa Pharmaceuticals worth $3.21K as of Q3 2026.
- AssetMark bought 38 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $2.8K.
- Kiniksa Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2903 holding.
- AssetMark first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
- 226 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.